{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T14:40:48Z","timestamp":1648910448838},"reference-count":29,"publisher":"Japanese Association of Virology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Uirusu"],"published-print":{"date-parts":[[2019]]},"DOI":"10.2222\/jsv.69.29","type":"journal-article","created":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T22:07:07Z","timestamp":1600207627000},"page":"29-36","source":"Crossref","is-referenced-by-count":0,"title":["HTLV-1-associated myelopathy"],"prefix":"10.2222","volume":"69","author":[{"given":"Yoshihisa","family":"YAMANO","sequence":"first","affiliation":[{"name":"Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1062","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1)\tOsame M, Usuku K, Izumo S, et al. HTLV-I associated myelopathy, a new clinical entity. Lancet 1:1031-1032, 1986.","DOI":"10.1016\/S0140-6736(86)91298-5"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2)\tBangham CR, Araujo A, Yamano Y, et al. HTLV-I-Associated Myelopathy\/ Tropical Spastic Paraparesis. Nat Rev Dis Primers. 1: 15012, 2015.","DOI":"10.1038\/nrdp.2015.23"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3)\tSatake M, Yamaguchi K and Tadokoro K. Current Prevalence of HTLV-1in Japan as Determined by Screening of Blood Donors. J Med Virol 84: 327-35, 2012.","DOI":"10.1002\/jmv.23181"},{"key":"4","unstructured":"4)\tEinsiedel L, Woodman RJ, Flynn M, et al. Human T-Lymphotropic Virus type 1 infection in an Indigenous Australian population: epidemiological insights from a hospital-based cohort study. BMC Public Health. 16:787, 2016."},{"key":"5","unstructured":"5)\tMartin F, Tagaya Y and Gallo R. Time to eradicate HTLV-1: an open letter to WHO. Lancet 391(10133): 1893-1894, 2018."},{"key":"6","unstructured":"6)\tSatake M, Iwanaga M, Sagara Y et al. Incidence of human T-lymphotropic virus 1 infection in adolescent and adult blood donors in Japan: a nationwide retrospective cohort analysis. Lancet Infect Dis 16: 1246-54, 2016."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7)\tYamauchi J, Yamano Y and Yuzawa K. Risk of Human T-cell Leukemia Virus Type 1 Infection in Kidney Transplantation. N Engl J Med, 380(3):296-298, 2019.","DOI":"10.1056\/NEJMc1809779"},{"key":"8","unstructured":"8)\tKaplan, J. E. et al. The risk of development of HTLV\u2011 I\u2011associated myelopathy\/tropical spastic paraparesis among persons infected with HTLV\u2011I. J. Acquir. Immune Defic. Syndr. 3: 1096\u20131101, 1990."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9)\tMaloney, E. M. et al. Incidence of HTLV\u2011I\u2011associated myelopathy\/tropical spastic paraparesis (HAM\/TSP) in Jamaica and Trinidad. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 17: 167\u2013170, 1998.","DOI":"10.1097\/00042560-199802010-00011"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10)\tMurphy, E. L. et al. HTLV-associated myelopathy in a cohort of HTLV\u2011I and HTLV\u2011II\u2011infected blood donors. The REDS investigators. Neurology 48: 315\u2013320, 1997.","DOI":"10.1212\/WNL.48.2.315"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11)\tOrland, J. R. et al. Prevalence and clinical features of HTLV neurologic disease in the HTLV Outcomes Study. Neurology 61: 1588\u20131594, 2003.","DOI":"10.1212\/01.WNL.0000096011.92542.DA"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12)\tSato T, Coler-Reilly ALG, Yagishita N, et al. Mogamulizumab (Anti-CCR4) in HTLV-1-Associated Myelopathy. N Engl J Med 378(6):529-538, 2018.","DOI":"10.1056\/NEJMoa1704827"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13)\tColer-Reilly ALG, et al. Nation-wide epidemiological study of Japanese patients with rare viral myelopathy using novel registration system (HAM-net). Orphanet J Rare Dis, 11(1):69, 2016.","DOI":"10.1186\/s13023-016-0451-x"},{"key":"14","unstructured":"14)\tIwanaga M, et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood, 116(8):1211, 2010."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15)\tSato T, Yagishita N, Tamaki K, et al. Proposal of Classification Criteria for HTLV-1-Associated Myelopathy\/Tropical Spastic Paraparesis Disease Activity. Front Microbiol. 9: 1651, 2018.","DOI":"10.3389\/fmicb.2018.01651"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16)\tSato T, Coler-Reilly A, Utsunomiya A, et al. CSF CXCL10, CXCL9, and Neopterin as Candidate Prognostic Biomarkers for HTLV-1-Associated Myelopathy\/Tropical Spastic Paraparesis. PLoS Negl Trop Dis 7(10): e2479, 2013.","DOI":"10.1371\/journal.pntd.0002479"},{"key":"17","unstructured":"17)\tMatsuura E, Nozuma S, Tashiro Y, et al. HTLV-1 associated myelopathy\/tropical spastic paraparesis (HAM\/TSP): A comparative study to identify factors that influence disease progression. J Neurol Sci. 371:112-116, 2016."},{"key":"18","unstructured":"18)\tNakagawa M, et al. HTLV-I-associated myelopathy: Analysis of 213 patients based on clinical features and laboratory findings. J Neurovirol, 1(1): 50-61, 1995."},{"key":"19","unstructured":"19)\tOlindo S, Lezin A, Cabre P, et al. HTLV-1 proviral load in peripheral blood mononuclear cells quantified in 100 HAM\/TSP patients: a marker of disease progression. J Neurol Sci 237: 53-9, 2005."},{"key":"20","unstructured":"20)\tNagai M, et al. Analysis of HTLV-I proviral load in 202 HAM\/TSP patients and 243 asymptomatic HTLV-I carriers: High proviral load strongly predisposes to HAM\/TSP. J Neurovirol, 4(6): 586-593, 1998."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21)\tJacobson S. Immunopathogenesis of human T cell lymphotropic virus type I-associated neurologic disease. J Infect Dis. 186:S187-192, 2002.","DOI":"10.1086\/344269"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22)\tZhou X, et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol 10: 1000-1007, 2009.","DOI":"10.1038\/ni.1774"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23)\tAraya N, et al. HTLV-1 induces a Th1-like state in CD4+CCR4+ T cells. J Clin Invest 124(8):3431-3442, 2014.","DOI":"10.1172\/JCI75250"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24)\tYamamoto-Taguchi N, et al. HTLV-1 bZIP Factor Induces Inflammation through Labile Foxp3 Expression. PLoS pathogens 9: e1003630, 2013.","DOI":"10.1371\/journal.ppat.1003630"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25)\tAndo H, et al. Positive feedback loop via astrocytes causes chronic inflammation in virus-associated myelopathy. Brain 136(9): 2876-2887, 2013.","DOI":"10.1093\/brain\/awt183"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26)\tYamauchi J, et al. Anti-CCR4 antibody mogamulizumab targets human T-lymphotropic virus type I-infected CD8+ as well as CD4+ T cells to treat associated myelopathy. J Infect Dis, 211:238-248, 2015.","DOI":"10.1093\/infdis\/jiu438"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27)\tFirouzi S, Farmanbar A, Nakai K, et al. Clonality of HTLV-1-infected T cells as a risk indicator for development and progression of adult T-cell leukemia. Blood Advances 1(15):1195-1205, 2017.","DOI":"10.1182\/bloodadvances.2017005900"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28)\tKobayashi S. et al. CADM1 expression and stepwise downregulation of CD7 are closely associated with clonal expansion of HTLV-I-infected cells in adult T-cell leukemia\/lymphoma. Clin Cancer Res, 20:2851-61, 2014.","DOI":"10.1158\/1078-0432.CCR-13-3169"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29)\tKataoka K, Nagata Y, Kitanaka A, et al. Integrated molecular analysis of adult T cell leukemia\/lymphoma. Nat Genet 47(11):1304-15, 2015.","DOI":"10.1038\/ng.3428"}],"container-title":["Uirusu"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsv\/69\/1\/69_29\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T03:51:06Z","timestamp":1600487466000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsv\/69\/1\/69_29\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2222\/jsv.69.29","relation":{},"ISSN":["0042-6857","1884-3433"],"issn-type":[{"value":"0042-6857","type":"print"},{"value":"1884-3433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]}}}